




RealRate

PHARMACEUTICAL 2020

Opus Genetics Inc
Rank 143 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Opus Genetics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Opus Genetics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Opus Genetics Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 277%, being 39% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	12,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,905
Liabilities, Non-Current	64
Other Assets	229
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	42
Other Net Income	2,580
Other Revenues	0
Property and Equipment	76
Research and Development	5,477
Selling, General and Administrative Expense	5,738

Output Variable	Value in 1000 USD
Assets	12,969
Liabilities	3,011
Expenses	11,215
Revenues	0
Stockholders Equity	9,958
Net Income	-8,635
Comprehensive Net Income	-8,635
BaseVar	14,887
ECR before Limited Liability	164%
Economic Capital Ratio	277%